Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virtus Biotech Clinical Trials ETF (NY:BBC)

49.80 +0.12 (+0.25%)
Streaming Delayed Price Updated: 12:17 PM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,508
Open 49.84
Bid (Size) 49.90 (300)
Ask (Size) 50.01 (500)
Prev. Close 49.67
Today's Range 49.59 - 50.70
52wk Range 20.87 - 54.95
Shares Outstanding 4,000
Dividend Yield 1.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Innovative ETF Strategies That Are Paying Off This Summer ↗
Amid record ETF inflows, niche funds like BBC, LATR, and FMED offer targeted exposure to biotech trials, buy-now-pay-later firms, and disruptive medicine, with notable recent returns. 
Via MarketBeat
Topics ETFs
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome. 
Via Stocktwits

Performance

YTD
+32.3%
+32.3%
1 Month
-2.5%
-2.5%
3 Month
+9.2%
+9.2%
6 Month
+18.3%
+18.3%
1 Year
+122.3%
+122.3%

More News

Read More
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
Via Stocktwits
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
Via Stocktwits
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
Via Stocktwits
News headline image
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
Via Benzinga
News headline image
ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On ↗
Via Benzinga
Topics ETFs Economy Stocks
News headline image
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode ↗
Via Stocktwits
Topics Government
News headline image
Why Is uniQure Stock Skyrocketing On Tuesday? ↗
Via Benzinga
News headline image
Inflation Cools In June, Triggers Spike In Laggard ETFs ↗
Via Talk Markets
Topics ETFs Economy
News headline image
5 ETFs Riding High On The Biotech Comeback ↗
Via Talk Markets
News headline image
Biotech ETF Tops in June: 5 Stocks That Outperform ↗
Via Talk Markets
News headline image
4 Sector ETFs That Survived Market Turmoil in June ↗
Via Talk Markets

Frequently Asked Questions

Is Virtus Biotech Clinical Trials ETF publicly traded?
Yes, Virtus Biotech Clinical Trials ETF is publicly traded.
What exchange does Virtus Biotech Clinical Trials ETF trade on?
Virtus Biotech Clinical Trials ETF trades on the New York Stock Exchange
What is the ticker symbol for Virtus Biotech Clinical Trials ETF?
The ticker symbol for Virtus Biotech Clinical Trials ETF is BBC on the New York Stock Exchange
What is the current price of Virtus Biotech Clinical Trials ETF?
The current price of Virtus Biotech Clinical Trials ETF is 49.80
When was Virtus Biotech Clinical Trials ETF last traded?
The last trade of Virtus Biotech Clinical Trials ETF was at 07/27/26 12:17 PM ET
What is the market capitalization of Virtus Biotech Clinical Trials ETF?
The market capitalization of Virtus Biotech Clinical Trials ETF is 199.18K
How many shares of Virtus Biotech Clinical Trials ETF are outstanding?
Virtus Biotech Clinical Trials ETF has 199K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.